Skip to content

A Prospective Cohort Study of Heart Patients Included in Exercise Based Rehabilitation in Oslo

Long-term Follow up of Exercise Based Cardiac Rehabilitation in Oslo

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02249260
Acronym
OsloHeartEx
Enrollment
160
Registered
2014-09-25
Start date
2011-03-31
Completion date
2020-12-31
Last updated
2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease

Keywords

Exercise, cardiac rehabilitation, quality of life

Brief summary

Outcomes evaluation is a critical component in outpatient cardiac rehabilitation. The aim of this study is to examine factors who predict long-term effects of improved peak oxygen uptake one year after participating in cardiac rehabilitation. Secondary to evaluate the short and long-term outcome of a 12-week outpatient cardiac rehabilitation program.

Detailed description

A prospective cohort study including all cardiac patients referred for outpatient cardiac rehabilitation in a primary care clinic in Oslo. The main efficacy variable is the changes in exercise capacity (VO2peak) as a primary prognostic measure of successful rehabilitation. HRQoL are measured by self-report using the COOP/WONCA questionnaire and SF-36.

Interventions

BEHAVIORALHigh intensity interval training

Group-based high-intensity aerobic interval training and lifestyle counseling

Sponsors

University of Oslo
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* stable coronary heart disease * valvular surgery * refered to high-intensity exercise training from a cardiologist

Exclusion criteria

* acute myocardial infarction within four week * serious rhythm disturbances * unstable angina pectoris * known significant comorbidity * symptomatic peripheral vascular disease * obstructive pulmonary disease with forced expiratory vital capacity \< 60% of predicted * left ventricular ejection fraction \< 40%

Design outcomes

Primary

MeasureTime frameDescription
Change in peak oxygen uptakebaseline, 15 monthsChange from baseline in peak oxygen uptake at 15 months

Secondary

MeasureTime frameDescription
Health related quality of lifebaseline, 12 weeksChanges from baseline in quality of life (COOP/WONCA and SF-36) at 12 weeks
Peak oxygen uptakebaseline, 12 weeksChange from baseline in peak oxygen uptake at 12 weeks
Time to exhaustionbaseline, 15 monthsChange from baseline in time to exhaustion at 15 months

Other

MeasureTime frameDescription
Systolic and diastolic Blood Pressurebaseline, 12 weeksChanges from baseline in systolic and diastolic blood pressure at 12 weeks

Countries

Norway

Contacts

Primary ContactBirgitta B Nilsson, PhD
b.b.nilsson@medisin.uio.no+4793210913
Backup ContactHelge Grimnes, MsC
helge.grimnes@oslo-universitetssykehus.no+4723015052

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026